Partnership marks AbbVie’s entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal with Danish company Gubra that aims to bring a long-acting amylin drug to ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

34,796 people played the daily Crossword recently. Can you solve it faster than others?34,796 people played the daily Crossword recently. Can you solve it faster than others?

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

Revenue: US$56.3b (up 3.7% from FY 2023). Net income: US$4.24b (down 12% from FY 2023). Profit margin: 7.5% (down from 8.9% in FY 2023). EPS: US$2.40 (down from US$2.73 in FY 2023). Revenue was in ...

AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...